Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (Q66410504)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study |
clinical trial |
Statements
SECOMBIT (English)
0 references
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation (English)
0 references
14 November 2016
0 references
April 2021
0 references
251
0 references
18 year
0 references